• Publications
  • Influence
Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.
Structure-guided lead optimization of recently described benzimidazolyl acetamides addressed the key liabilities of the previous lead compound 1. These efforts culminated in the discovery ofExpand
  • 58
  • 3
Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes.
Herein we describe the synthesis and structure activity relationship of a new class of FXR agonists identified from a high-throughput screening campaign. Further optimization of the original hits ledExpand
  • 53
  • 3
Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
  • Song Feng, Minmin Yang, +11 authors L. Chen
  • Chemistry, Medicine
  • Bioorganic & medicinal chemistry letters
  • 1 May 2009
According to the docking studies and the analysis of a co-crystal structure of GW4064 with FXR, a series of 3-aryl heterocyclic isoxazole analogs were designed and synthesized. N-Oxide pyridineExpand
  • 48
  • 2
Broad spectrum antibacterial activity of a mixture of isothiocyanates from nasturtium (Tropaeoli majoris herba) and horseradish (Armoraciae rusticanae radix).
Isothiocyanates have been reported to exert antimicrobial activity. These compounds are found in a licensed native preparation of nasturtium (Tropaeoli majoris herba) and horseradish (ArmoraciaeExpand
  • 28
  • 1
Design, Synthesis, and Evaluation of 2β-Alkenyl Penam Sulfone Acids as Inhibitors of β-Lactamases†
A general method for synthesis of 2β-alkenyl penam sulfones has been developed. The new compounds inhibited most of the common types of β-lactamase. The level of activity depended very strongly onExpand
  • 64
  • 1
2‐Phenoxy‐nicotinamides are Potent Agonists at the Bile Acid Receptor GPBAR1 (TGR5)
Potency with potential: 2-Phenoxy-nicotinamides were identified as potent agonists at the GPBAR1 receptor, a target in the treatment of obesity, type 2 diabetes and metabolic syndrome. ExtensiveExpand
  • 21
  • 1
Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs.
We reported earlier the refinement of our initial five-point pharmacophore model for the Histamine 3 receptor (H(3)R), with a new acceptor feature important for binding and selectivity against theExpand
  • 21
  • 1
Studies in mice, hamsters, and rats demonstrate that repression of hepatic apoA-I expression by taurocholic acid in mice is not mediated by the farnesoid-X-receptor
It is claimed that apoA-I expression is repressed in mice by cholic acid (CA) and its taurine conjugate, taurocholic acid (TCA) via farnesoid X receptor (FXR) activation. We measured apoA-IExpand
  • 14
  • 1
Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.
A general method for synthesis of 2 beta-alkenyl penam sulfones has been developed. The new compounds inhibited most of the common types of beta-lactamase. The level of activity depended veryExpand
  • 4
  • 1
5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity.
Obesity is a major risk factor in the development of conditions such as hypertension, hyperglycemia, dyslipidemia, coronary artery disease, and cancer. Several pieces of evidence across differentExpand
  • 30